Immunodeficiency and intrinsic IFN resistance are associated with viral breakthrough to HCV therapy in HIV-coinfected patients.
Nussenblatt, Veronique; McLaughlin, Mary; Rehm, Catherine A; Lempicki, Richard A; Brann, Terry; Yang, Jun; Proschan, Michael; Highbarger, Helene C; Dewar, Robin L; Imamichi, Tom; Koratich, Chad; Neumann, Avidan U; Masur, Henry; Polis, Michael A; Kottilil, Shyam.
AIDS Res Hum Retroviruses
; 23(11): 1354-9, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18184077
Inter and intrapatient evolution of hepatitis C virus.
Guarding the frontiers: the biology of type III interferons.
Bringing the Hepatitis C Virus to Life.
Modeling viral evolutionary dynamics after telaprevir-based treatment.
The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia.
IL28B and the control of hepatitis C virus infection.
[VIRAL HEPATITIS C: EVOLUTION OF THE EPIDEMIOLOGIC PROCESS, EVOLUTION OF THE VIRUS].
Imunitní odpoved v patogenezi infekce virem hepatitidy C.
Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
Insights into the role of HCV Plus-/Minus strand RNA, IFN-Î³ and IL-29 in relapse outcome in patients infected with HCV.